Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
5
×
Tags
boston blog main
boston top stories
5
×
clinical trials
fda
5
×
life sciences
national blog main
biotech
national top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
indiana blog main
indiana top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
boston
calcitonin gene-related peptide
drugs
eptinezumab
erenumab
fremanezumab
galcanezumab
migraine research foundation
national
teva pharmaceutical
What
approval
5
×
drug
fda
won
class
developed
medicines
migraine
new
nod
oral
agency
ago
aimmune
allergy
alnylam
amgen
approved
arguments
awarded
big
blueprint
cancer
candidate
candidates
commercialized
companies
competitors
currently
decades
drugs
friday
gets
head
immunotherapy
indicated
interference
late
make
marketing
Language
unset
Current search:
photo
×
" boston top stories "
×
fda
×
approval
×
@xconomy.com
4 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines